The US Food and Drug Administration (FDA) has approved the DF4 high-voltage connector system (Medtronic). This is a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
The DF4 connector system helps simplify implantation procedures via a redesigned port and provides additional reliability by giving physicians visual confirmation of the lead connection to the device.
This connector uses the same lead body as Medtronic’s Sprint Quattro lead, which has more than a decade of proven performance and a high safety and efficacy profile.
The DF4 design includes fewer connections between the device and the defibrillation leads. Prior to the development of the DF4, traditional high-voltage connector systems required up to three connections. The DF4 connector has a single set-screw to connect the lead to the device and is available on several Medtronic ICDs and CRT-Ds, including the Protecta, Consulta and Secura portfolio of implantable defibrillators.
“With the availability of the DF4 system, implanting physicians now have access to the newest industry standard designed specifically around implant simplicity and system reliability,” said Brian Ramza, Evangeline and Frank Thompson chair in electrophysiology at the St Luke’s Mid America Heart Institute, Kansas City, USA. “This innovation addresses our need for easy-to-use, reliable technology that helps shorten the overall procedure time without compromising safety.”
In addition to the USA, the DF4 high-voltage connector system is approved for use and available in Europe, Japan, Canada, and Australia.
